Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_assertion type Assertion NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_head.
- NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_assertion description "[Although we still have a long way to go before an effective and nontoxic miRNA-based cancer therapy can be introduced into the clinic, the inhibition of integrin ?5 expression by targeting miR-92a needs to be explored further for future applications in ovarian cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_provenance.
- NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_assertion evidence source_evidence_literature NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_provenance.
- NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_assertion SIO_000772 23499550 NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_provenance.
- NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_assertion wasDerivedFrom befree-20150227 NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_provenance.
- NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_assertion wasGeneratedBy ECO_0000203 NP516655.RAVShgrWhXRtJ4RgL2xSxAhakPUkLvyVypP0UKHyEoaNg130_provenance.